title: Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek.
abstract: Lymphoseek is a molecular imaging agent specifically designed for sentinel lymph node (SLN) mapping. We conducted a Phase I trial which measured the injection site clearance and SLN accumulation after a single intra dermal injection of Lymphoseek or [99mTc]sulfur colloid protocol. Ten patients with breast cancer participated in this study. Five patients received an intradermal administration of 1.0 nmol of 99mTc-labeled Lymphoseek and five patients received an intradermal administration of filtered [99mTc]sulfur colloid (fTcSC). Lymphoseek exhibited a significantly (P<.001) faster injection site clearance than fTcSC. The mean Lymphoseek clearance half-time was 2.61+/-0.72 h compared to 24.1+/-17.7 h for fTcSC. The mean SLN uptake of Lymphoseek (1.1+/-.5%) and fTcSC (2.5+/-4.9%) was statistically equivalent (P=.28). When an intra dermal injection was employed, Lymphoseek demonstrated faster injection site clearance than fTcSC.
authors.affiliation: Department of Surgery, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Wallace
authors.forename: Carl K
authors.initials: CK
authors.lastname: Hoh
authors.forename: Denise D
authors.initials: DD
authors.lastname: Darrah
authors.forename: Gery
authors.initials: G
authors.lastname: Schulteis
authors.forename: David R
authors.initials: DR
authors.lastname: Vera
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D003911:Dextrans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008198:Lymph Nodes / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008351:Mannans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D015609:Organotechnetium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics; D021701:Sentinel Lymph Node Biopsy / Q000379:methods; D016284:Technetium Tc 99m Pentetate / Q000031:analogs & derivatives; D014018:Tissue Distribution
chemical_list: D003911:Dextrans; D008351:Mannans; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C431884:technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran; D004369:Pentetic Acid; D016284:Technetium Tc 99m Pentetate